Bruce E. Maryanoff
Research Subjects
Research Interests
Bruce E. Maryanoff has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Patricia Andrade-Gordon
Johnson and Johnson Pharmaceutical Research and Development
5 shared publicationsDavid F. McComsey
Research & Early Development, Johnson & Johnson Pharmaceutical Research & Development, Spring House, Pennsylvania 19477-0776
3 shared publicationsHan-Cheng Zhang
Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development, Spring House, PA, USA
3 shared publicationsLawrence de Garavilla
Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477-0776, USA
3 shared publicationsMichael J. Costanzo
3 shared publications- Alexey B. Dyatkin
Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477-0776, USA
2 shared publications
Latest Publications
- 1 August 2009
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 9 (11) , 1049-1062
Sugar Sulfamates for Seizure Control: Discovery and Development of Topiramate, a Structurally Unique Antiepileptic Drug
TOPAMAX® (topiramate) 1, is a broad-spectrum anticonvulsant that has been marketed worldwide for the treatment of epilepsy and migraine. We discovered this blockbuster drug serendipitously in a project that originally sought a new antidiabetic agent. Topiramate has useful neurological effects that derive from multiple CNS mechanisms of action, but it is basically a “neurostabilizer” by virtue of attenuating the excitability of brain neuronal pathways. During its extensive clinical use, topiramate was also found to possess antimetabolic dysfunction activity, which could be applicable in the treatment of diabetes and obesity. This article discusses research results and events surrounding the discovery and development of topiramate.
- 1 August 2009
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 9 (11) , 1049-1062
Sugar Sulfamates for Seizure Control: Discovery and Development of Topiramate, a Structurally Unique Antiepileptic Drug
TOPAMAX® (topiramate) 1, is a broad-spectrum anticonvulsant that has been marketed worldwide for the treatment of epilepsy and migraine. We discovered this blockbuster drug serendipitously in a project that originally sought a new antidiabetic agent. Topiramate has useful neurological effects that derive from multiple CNS mechanisms of action, but it is basically a “neurostabilizer” by virtue of attenuating the excitability of brain neuronal pathways. During its extensive clinical use, topiramate was also found to possess antimetabolic dysfunction activity, which could be applicable in the treatment of diabetes and obesity. This article discusses research results and events surrounding the discovery and development of topiramate.
- 13 October 2008
- Published by Springer Nature
- p. 205-236
Thrombin Receptor Modulators: Medicinal Chemistry, Biological Evaluation, and Clinical Application
- 13 October 2008
- Published by Springer Nature
- p. 205-236
Thrombin Receptor Modulators: Medicinal Chemistry, Biological Evaluation, and Clinical Application
- 24 June 2008
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (25) , 8513-8518
Thrombogenic collagen-mimetic peptides: Self-assembly of triple helix-based fibrils driven by hydrophobic interactions
Collagens are integral structural proteins in animal tissues and play key functional roles in cellular modulation. We sought to discover collagen model peptides (CMPs) that would form triple helices and self-assemble into supramolecular fibrils exhibiting collagen-like biological activity without preorganizing the peptide chains by covalent linkages. This challenging objective was accomplished by placing aromatic groups on the ends of a representative 30-mer CMP, (GPO) 10 , as with l -phenylalanine and l -pentafluorophenylalanine in 32-mer 1a. Computational studies on homologous 29-mers 1a′–d′ (one less GPO), as pairs of triple helices interacting head-to-tail, yielded stabilization energies in the order 1a′ > 1b′ > 1c′ > 1d′, supporting the hypothesis that hydrophobic aromatic groups can drive CMP self-assembly. Peptides 1a–d were studied comparatively relative to structural properties and ability to stimulate human platelets. Although each 32-mer formed stable triple helices (CD) spectroscopy, only 1a and 1b self-assembled into micrometer-scale fibrils. Light microscopy images for 1a depicted long collagen-like fibrils, whereas images for 1d did not. Atomic force microscopy topographical images indicated that 1a and 1b self-organize into microfibrillar species, whereas 1c and 1d do not. Peptides 1a and 1b induced the aggregation of human blood platelets with a potency similar to type I collagen, whereas 1c was much less effective, and 1d was inactive (EC 50 potency: 1a/1b ≫ 1c > 1d). Thus, 1a and 1b spontaneously self-assemble into thrombogenic collagen-mimetic materials because of hydrophobic aromatic interactions provided by the special end-groups. These findings have important implications for the design of biofunctional CMPs.
- 24 June 2008
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (25) , 8513-8518
Thrombogenic collagen-mimetic peptides: Self-assembly of triple helix-based fibrils driven by hydrophobic interactions
Collagens are integral structural proteins in animal tissues and play key functional roles in cellular modulation. We sought to discover collagen model peptides (CMPs) that would form triple helices and self-assemble into supramolecular fibrils exhibiting collagen-like biological activity without preorganizing the peptide chains by covalent linkages. This challenging objective was accomplished by placing aromatic groups on the ends of a representative 30-mer CMP, (GPO) 10 , as with l -phenylalanine and l -pentafluorophenylalanine in 32-mer 1a. Computational studies on homologous 29-mers 1a′–d′ (one less GPO), as pairs of triple helices interacting head-to-tail, yielded stabilization energies in the order 1a′ > 1b′ > 1c′ > 1d′, supporting the hypothesis that hydrophobic aromatic groups can drive CMP self-assembly. Peptides 1a–d were studied comparatively relative to structural properties and ability to stimulate human platelets. Although each 32-mer formed stable triple helices (CD) spectroscopy, only 1a and 1b self-assembled into micrometer-scale fibrils. Light microscopy images for 1a depicted long collagen-like fibrils, whereas images for 1d did not. Atomic force microscopy topographical images indicated that 1a and 1b self-organize into microfibrillar species, whereas 1c and 1d do not. Peptides 1a and 1b induced the aggregation of human blood platelets with a potency similar to type I collagen, whereas 1c was much less effective, and 1d was inactive (EC 50 potency: 1a/1b ≫ 1c > 1d). Thus, 1a and 1b spontaneously self-assemble into thrombogenic collagen-mimetic materials because of hydrophobic aromatic interactions provided by the special end-groups. These findings have important implications for the design of biofunctional CMPs.
- 14 May 2008
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 14 (2) , 120-142
Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate
Topiramate (TPM; TOPAMAX®) is a broad‐spectrum antiepileptic drug (AED) that is approved in many world markets for preventing or reducing the frequency of epileptic seizures (as monotherapy or adjunctive therapy), and for the prophylaxis of migraine. TPM, a sulfamate derivative of the naturally occurring sugar D‐fructose, possesses several pharmacodynamic properties that may contribute to its clinically useful attributes, and to its observed adverse effects. The sulfamate moiety is essential, but not sufficient, for its pharmacodynamic properties. In this review, we discuss the known pharmacodynamic and pharmacokinetic properties of TPM, as well as its various clinically beneficial and adverse effects.
- 14 May 2008
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 14 (2) , 120-142
Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate
Topiramate (TPM; TOPAMAX®) is a broad‐spectrum antiepileptic drug (AED) that is approved in many world markets for preventing or reducing the frequency of epileptic seizures (as monotherapy or adjunctive therapy), and for the prophylaxis of migraine. TPM, a sulfamate derivative of the naturally occurring sugar D‐fructose, possesses several pharmacodynamic properties that may contribute to its clinically useful attributes, and to its observed adverse effects. The sulfamate moiety is essential, but not sufficient, for its pharmacodynamic properties. In this review, we discuss the known pharmacodynamic and pharmacokinetic properties of TPM, as well as its various clinically beneficial and adverse effects.
- 8 May 2008
- Published by Wiley in ChemMedChem
- Vol. 3 (5) , 732-736
Carba‐nucleosides as Potent Antagonists of the Adenosine 5′‐Diphosphate (ADP) Purinergic Receptor (P2Y12) on Human Platelets
- 8 May 2008
- Published by Wiley in ChemMedChem
- Vol. 3 (5) , 732-736
Carba‐nucleosides as Potent Antagonists of the Adenosine 5′‐Diphosphate (ADP) Purinergic Receptor (P2Y12) on Human Platelets
- 26 March 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (8) , 2518-2521
Carbonic Anhydrase-II Inhibition. What are the True Enzyme–Inhibitory Properties of the Sulfamide Cognate of Topiramate?
The marketed drug topiramate (1) is a moderate inhibitor of carbonic anhydrase-II (CA-II) (Ki or Kd = 0.3–0.6 µM), whereas sulfamide cognate 2 is a comparatively weak inhibitor (Ki or Kd = 25–650 µM). From an X-ray cocrystal structure of 2·CA-II, Winum et al. (J. Med. Chem. 2006, 49, 7024) proposed that an adverse steric interaction between the C8 methyl group in 2 and Ala-65 of CA-II is responsible for the diminished CA-II inhibitory potency of 2. We performed a straightforward test of this Ala-65 effect by synthesizing and examining ligand 3, which lacks the offending (pro-S or C8) methyl substituent in 2. We also prepared and evaluated related sulfamides 5, 7, and 9. In a CA-II inhibition assay (4-nitrophenyl acetate), the Ki for 3 was ∼300 µM, indicating very weak inhibition, close to that for 2 (4NPA, Ki = 340 µM). In a CA-II binding assay (ThermoFluor), the Kd for 3 was >57 µM, indicating very weak binding, lower than the affinity of 2 (Kd = 25 µM). Our results draw into question the proposed steric interaction between the C8 methyl of 2 and Ala-65 of CA-II.
- 26 March 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (8) , 2518-2521
Carbonic Anhydrase-II Inhibition. What are the True Enzyme–Inhibitory Properties of the Sulfamide Cognate of Topiramate?
The marketed drug topiramate (1) is a moderate inhibitor of carbonic anhydrase-II (CA-II) (Ki or Kd = 0.3–0.6 µM), whereas sulfamide cognate 2 is a comparatively weak inhibitor (Ki or Kd = 25–650 µM). From an X-ray cocrystal structure of 2·CA-II, Winum et al. (J. Med. Chem. 2006, 49, 7024) proposed that an adverse steric interaction between the C8 methyl group in 2 and Ala-65 of CA-II is responsible for the diminished CA-II inhibitory potency of 2. We performed a straightforward test of this Ala-65 effect by synthesizing and examining ligand 3, which lacks the offending (pro-S or C8) methyl substituent in 2. We also prepared and evaluated related sulfamides 5, 7, and 9. In a CA-II inhibition assay (4-nitrophenyl acetate), the Ki for 3 was ∼300 µM, indicating very weak inhibition, close to that for 2 (4NPA, Ki = 340 µM). In a CA-II binding assay (ThermoFluor), the Kd for 3 was >57 µM, indicating very weak binding, lower than the affinity of 2 (Kd = 25 µM). Our results draw into question the proposed steric interaction between the C8 methyl of 2 and Ala-65 of CA-II.
- 15 February 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 16 (4) , 1562-1595
Inhibitors of proteases and amide hydrolases that employ an α-ketoheterocycle as a key enabling functionality
- 15 February 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 16 (4) , 1562-1595
Inhibitors of proteases and amide hydrolases that employ an α-ketoheterocycle as a key enabling functionality
- 6 September 2006
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 39 (11) , 831-840
Adventures in Drug Discovery: Potent Agents Based on Ligands for Cell-Surface Receptors
How does one go about discovering new drugs? This question is addressed by descriptions of drug discovery research in three project areas that pertain to antagonist ligands for cell-surface receptors. The molecular targets of interest are protease-activated receptor-1 (PAR-1), vasopressin receptors (V1a and V2 subtypes), and the fibrinogen receptor (GPIIb/IIIa). I present different approaches to the identification of high-affinity ligands for these receptors, en route to drug candidates. The PAR-1 project resulted in a pharmacological tool compound that facilitated in vivo proof-of-principle studies, whereas the vasopressin and fibrinogen receptor projects resulted in several preclinical development compounds, three of which advanced into human clinical trials.
- 6 September 2006
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 39 (11) , 831-840
Adventures in Drug Discovery: Potent Agents Based on Ligands for Cell-Surface Receptors
How does one go about discovering new drugs? This question is addressed by descriptions of drug discovery research in three project areas that pertain to antagonist ligands for cell-surface receptors. The molecular targets of interest are protease-activated receptor-1 (PAR-1), vasopressin receptors (V1a and V2 subtypes), and the fibrinogen receptor (GPIIb/IIIa). I present different approaches to the identification of high-affinity ligands for these receptors, en route to drug candidates. The PAR-1 project resulted in a pharmacological tool compound that facilitated in vivo proof-of-principle studies, whereas the vasopressin and fibrinogen receptor projects resulted in several preclinical development compounds, three of which advanced into human clinical trials.
- Open Access
- 1 August 2006
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 68 (2) , 113-119
Examination of Two Independent Kinetic Assays for Determining the Inhibition of Carbonic Anhydrases I and II: Structure?Activity Comparison of Sulfamates and Sulfamides
- 1 August 2006
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 68 (2) , 113-119
Open AccessExamination of Two Independent Kinetic Assays for Determining the Inhibition of Carbonic Anhydrases I and II: Structure?Activity Comparison of Sulfamates and Sulfamides
- 1 July 2006
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 68 (1) , 29-36
Exploration of Potential Prodrugs of RWJ‐445167, an Oxyguanidine‐based Dual Inhibitor of Thrombin and Factor Xa
Compound 2 (RWJ‐445167; 3DP‐10017), a dual inhibitor of thrombin and factor Xa, was advanced into human clinical studies. However, its oral bioavailability in humans proved to be below acceptable limits. To address this issue, we explored a prodrug approach involving numerous guanidine derivatives. Prodrug candidates of classes A (carbamate derivatives), B (imidate derivatives), and C (alkyl and acyl derivatives), compounds 3–6, were synthesized and evaluated for anticoagulant activity at 2h after oral administration to rats. In comparison to the parent drug (2), little worthwhile improvement was observed for the prodrug candidates.
- 1 July 2006
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 68 (1) , 29-36
Exploration of Potential Prodrugs of RWJ‐445167, an Oxyguanidine‐based Dual Inhibitor of Thrombin and Factor Xa
Compound 2 (RWJ‐445167; 3DP‐10017), a dual inhibitor of thrombin and factor Xa, was advanced into human clinical studies. However, its oral bioavailability in humans proved to be below acceptable limits. To address this issue, we explored a prodrug approach involving numerous guanidine derivatives. Prodrug candidates of classes A (carbamate derivatives), B (imidate derivatives), and C (alkyl and acyl derivatives), compounds 3–6, were synthesized and evaluated for anticoagulant activity at 2h after oral administration to rats. In comparison to the parent drug (2), little worthwhile improvement was observed for the prodrug candidates.